ID   UBE3C_HUMAN             Reviewed;        1083 AA.
AC   Q15386; A4D235; A6NCP3; Q8TC15; Q96CR4; Q9UDU3;
DT   07-JUN-2005, integrated into UniProtKB/Swiss-Prot.
DT   07-JUN-2005, sequence version 3.
DT   28-JUN-2023, entry version 186.
DE   RecName: Full=Ubiquitin-protein ligase E3C {ECO:0000305};
DE            EC=2.3.2.26 {ECO:0000269|PubMed:11278995, ECO:0000269|PubMed:24811749, ECO:0000269|PubMed:25752573, ECO:0000269|PubMed:25752577, ECO:0000269|PubMed:32039437, ECO:0000269|PubMed:33637724, ECO:0000269|PubMed:34239127};
DE   AltName: Full=HECT-type ubiquitin transferase E3C {ECO:0000305};
DE   AltName: Full=Homologous to E6AP carboxyl terminus homologous protein 2 {ECO:0000303|PubMed:9575161};
DE            Short=HectH2 {ECO:0000303|PubMed:9575161};
DE   AltName: Full=RTA-associated ubiquitin ligase {ECO:0000303|PubMed:21167755};
DE            Short=RAUL {ECO:0000303|PubMed:21167755};
GN   Name=UBE3C {ECO:0000303|PubMed:17323924, ECO:0000312|HGNC:HGNC:16803};
GN   Synonyms=KIAA0010 {ECO:0000303|PubMed:7584026}, KIAA10
GN   {ECO:0000303|PubMed:11278995};
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Bone marrow;
RX   PubMed=7584026; DOI=10.1093/dnares/1.1.27;
RA   Nomura N., Miyajima N., Sazuka T., Tanaka A., Kawarabayasi Y., Sato S.,
RA   Nagase T., Seki N., Ishikawa K., Tabata S.;
RT   "Prediction of the coding sequences of unidentified human genes. I. The
RT   coding sequences of 40 new genes (KIAA0001-KIAA0040) deduced by analysis of
RT   randomly sampled cDNA clones from human immature myeloid cell line KG-1.";
RL   DNA Res. 1:27-35(1994).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=12853948; DOI=10.1038/nature01782;
RA   Hillier L.W., Fulton R.S., Fulton L.A., Graves T.A., Pepin K.H.,
RA   Wagner-McPherson C., Layman D., Maas J., Jaeger S., Walker R., Wylie K.,
RA   Sekhon M., Becker M.C., O'Laughlin M.D., Schaller M.E., Fewell G.A.,
RA   Delehaunty K.D., Miner T.L., Nash W.E., Cordes M., Du H., Sun H.,
RA   Edwards J., Bradshaw-Cordum H., Ali J., Andrews S., Isak A., Vanbrunt A.,
RA   Nguyen C., Du F., Lamar B., Courtney L., Kalicki J., Ozersky P.,
RA   Bielicki L., Scott K., Holmes A., Harkins R., Harris A., Strong C.M.,
RA   Hou S., Tomlinson C., Dauphin-Kohlberg S., Kozlowicz-Reilly A., Leonard S.,
RA   Rohlfing T., Rock S.M., Tin-Wollam A.-M., Abbott A., Minx P., Maupin R.,
RA   Strowmatt C., Latreille P., Miller N., Johnson D., Murray J.,
RA   Woessner J.P., Wendl M.C., Yang S.-P., Schultz B.R., Wallis J.W.,
RA   Spieth J., Bieri T.A., Nelson J.O., Berkowicz N., Wohldmann P.E.,
RA   Cook L.L., Hickenbotham M.T., Eldred J., Williams D., Bedell J.A.,
RA   Mardis E.R., Clifton S.W., Chissoe S.L., Marra M.A., Raymond C., Haugen E.,
RA   Gillett W., Zhou Y., James R., Phelps K., Iadanoto S., Bubb K., Simms E.,
RA   Levy R., Clendenning J., Kaul R., Kent W.J., Furey T.S., Baertsch R.A.,
RA   Brent M.R., Keibler E., Flicek P., Bork P., Suyama M., Bailey J.A.,
RA   Portnoy M.E., Torrents D., Chinwalla A.T., Gish W.R., Eddy S.R.,
RA   McPherson J.D., Olson M.V., Eichler E.E., Green E.D., Waterston R.H.,
RA   Wilson R.K.;
RT   "The DNA sequence of human chromosome 7.";
RL   Nature 424:157-164(2003).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=12690205; DOI=10.1126/science.1083423;
RA   Scherer S.W., Cheung J., MacDonald J.R., Osborne L.R., Nakabayashi K.,
RA   Herbrick J.-A., Carson A.R., Parker-Katiraee L., Skaug J., Khaja R.,
RA   Zhang J., Hudek A.K., Li M., Haddad M., Duggan G.E., Fernandez B.A.,
RA   Kanematsu E., Gentles S., Christopoulos C.C., Choufani S., Kwasnicka D.,
RA   Zheng X.H., Lai Z., Nusskern D.R., Zhang Q., Gu Z., Lu F., Zeesman S.,
RA   Nowaczyk M.J., Teshima I., Chitayat D., Shuman C., Weksberg R.,
RA   Zackai E.H., Grebe T.A., Cox S.R., Kirkpatrick S.J., Rahman N.,
RA   Friedman J.M., Heng H.H.Q., Pelicci P.G., Lo-Coco F., Belloni E.,
RA   Shaffer L.G., Pober B., Morton C.C., Gusella J.F., Bruns G.A.P., Korf B.R.,
RA   Quade B.J., Ligon A.H., Ferguson H., Higgins A.W., Leach N.T.,
RA   Herrick S.R., Lemyre E., Farra C.G., Kim H.-G., Summers A.M., Gripp K.W.,
RA   Roberts W., Szatmari P., Winsor E.J.T., Grzeschik K.-H., Teebi A.,
RA   Minassian B.A., Kere J., Armengol L., Pujana M.A., Estivill X.,
RA   Wilson M.D., Koop B.F., Tosi S., Moore G.E., Boright A.P., Zlotorynski E.,
RA   Kerem B., Kroisel P.M., Petek E., Oscier D.G., Mould S.J., Doehner H.,
RA   Doehner K., Rommens J.M., Vincent J.B., Venter J.C., Li P.W., Mural R.J.,
RA   Adams M.D., Tsui L.-C.;
RT   "Human chromosome 7: DNA sequence and biology.";
RL   Science 300:767-772(2003).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 2 AND 3).
RC   TISSUE=Lung, and Placenta;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [6]
RP   PARTIAL PROTEIN SEQUENCE, FUNCTION, CATALYTIC ACTIVITY, PATHWAY,
RP   INTERACTION WITH UBE2D1, AUTOUBIQUITINATION, AND TISSUE SPECIFICITY.
RX   PubMed=11278995; DOI=10.1074/jbc.m100034200;
RA   You J., Pickart C.M.;
RT   "A HECT domain E3 enzyme assembles novel polyubiquitin chains.";
RL   J. Biol. Chem. 276:19871-19878(2001).
RN   [7]
RP   FUNCTION, INTERACTION WITH UBE2D1 AND UBE2L3, AND TISSUE SPECIFICITY.
RX   PubMed=9575161; DOI=10.1074/jbc.273.20.12148;
RA   Schwarz S.E., Rosa J.L., Scheffner M.;
RT   "Characterization of human hect domain family members and their interaction
RT   with UbcH5 and UbcH7.";
RL   J. Biol. Chem. 273:12148-12154(1998).
RN   [8]
RP   FUNCTION IN CAND2 UBIQUITINATION, PATHWAY, INTERACTION WITH CAND2 AND 26S
RP   PROTEASOMES, ACTIVE SITE, MUTAGENESIS OF CYS-1051, AND TISSUE SPECIFICITY.
RX   PubMed=12692129; DOI=10.1074/jbc.m212887200;
RA   You J., Wang M., Aoki T., Tamura T.-A., Pickart C.M.;
RT   "Proteolytic targeting of transcriptional regulator TIP120B by a HECT
RT   domain E3 ligase.";
RL   J. Biol. Chem. 278:23369-23375(2003).
RN   [9]
RP   FUNCTION.
RX   PubMed=16341092; DOI=10.1038/sj.emboj.7600895;
RA   Wang M., Pickart C.M.;
RT   "Different HECT domain ubiquitin ligases employ distinct mechanisms of
RT   polyubiquitin chain synthesis.";
RL   EMBO J. 24:4324-4333(2005).
RN   [10]
RP   FUNCTION, PATHWAY, AND IDENTIFICATION BY MASS SPECTROMETRY.
RX   PubMed=16601690; DOI=10.1038/sj.emboj.7601061;
RA   Wang M., Cheng D., Peng J., Pickart C.M.;
RT   "Molecular determinants of polyubiquitin linkage selection by an HECT
RT   ubiquitin ligase.";
RL   EMBO J. 25:1710-1719(2006).
RN   [11]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Embryonic kidney;
RX   PubMed=17323924; DOI=10.1021/bi061994u;
RA   Wang X., Chen C.-F., Baker P.R., Chen P.-L., Kaiser P., Huang L.;
RT   "Mass spectrometric characterization of the affinity-purified human 26S
RT   proteasome complex.";
RL   Biochemistry 46:3553-3565(2007).
RN   [12]
RP   FUNCTION, PATHWAY, ACTIVE SITE, AND MUTAGENESIS OF CYS-1051.
RX   PubMed=21167755; DOI=10.1016/j.immuni.2010.11.027;
RA   Yu Y., Hayward G.S.;
RT   "The ubiquitin E3 ligase RAUL negatively regulates type i interferon
RT   through ubiquitination of the transcription factors IRF7 and IRF3.";
RL   Immunity 33:863-877(2010).
RN   [13]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T.,
RA   Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [14]
RP   FUNCTION, CATALYTIC ACTIVITY, PATHWAY, ACTIVE SITE, AND MUTAGENESIS OF
RP   CYS-1051.
RX   PubMed=24811749; DOI=10.1002/embj.201386906;
RA   Besche H.C., Sha Z., Kukushkin N.V., Peth A., Hock E.M., Kim W., Gygi S.,
RA   Gutierrez J.A., Liao H., Dick L., Goldberg A.L.;
RT   "Autoubiquitination of the 26S proteasome on Rpn13 regulates breakdown of
RT   ubiquitin conjugates.";
RL   EMBO J. 33:1159-1176(2014).
RN   [15]
RP   FUNCTION, INTERACTION WITH THE 26S PROTEASOME, CATALYTIC ACTIVITY, PATHWAY,
RP   ACTIVE SITE, AND MUTAGENESIS OF CYS-1051.
RX   PubMed=24158444; DOI=10.1074/jbc.m113.499350;
RA   Chu B.W., Kovary K.M., Guillaume J., Chen L.C., Teruel M.N., Wandless T.J.;
RT   "The E3 ubiquitin ligase UBE3C enhances proteasome processivity by
RT   ubiquitinating partially proteolyzed substrates.";
RL   J. Biol. Chem. 288:34575-34587(2013).
RN   [16]
RP   FUNCTION, CATALYTIC ACTIVITY, ACTIVE SITE, AUTOUBIQUITINATION, PATHWAY, AND
RP   MUTAGENESIS OF CYS-1051.
RX   PubMed=25752573; DOI=10.1016/j.molcel.2015.01.041;
RA   Kristariyanto Y.A., Abdul Rehman S.A., Campbell D.G., Morrice N.A.,
RA   Johnson C., Toth R., Kulathu Y.;
RT   "K29-selective ubiquitin binding domain reveals structural basis of
RT   specificity and heterotypic nature of K29 polyubiquitin.";
RL   Mol. Cell 58:83-94(2015).
RN   [17]
RP   FUNCTION, CATALYTIC ACTIVITY, AND PATHWAY.
RX   PubMed=25752577; DOI=10.1016/j.molcel.2015.01.042;
RA   Michel M.A., Elliott P.R., Swatek K.N., Simicek M., Pruneda J.N.,
RA   Wagstaff J.L., Freund S.M., Komander D.;
RT   "Assembly and specific recognition of K29- and K33-linked polyubiquitin.";
RL   Mol. Cell 58:95-109(2015).
RN   [18]
RP   FUNCTION.
RX   PubMed=28396413; DOI=10.1073/pnas.1701734114;
RA   Kuo C.L., Goldberg A.L.;
RT   "Ubiquitinated proteins promote the association of proteasomes with the
RT   deubiquitinating enzyme Usp14 and the ubiquitin ligase Ube3c.";
RL   Proc. Natl. Acad. Sci. U.S.A. 114:E3404-E3413(2017).
RN   [19]
RP   FUNCTION.
RX   PubMed=31375563; DOI=10.1074/jbc.ra119.009654;
RA   Gottlieb C.D., Thompson A.C.S., Ordureau A., Harper J.W., Kopito R.R.;
RT   "Acute unfolding of a single protein immediately stimulates recruitment of
RT   ubiquitin protein ligase E3C (UBE3C) to 26S proteasomes.";
RL   J. Biol. Chem. 294:16511-16524(2019).
RN   [20]
RP   FUNCTION, CATALYTIC ACTIVITY, AND PATHWAY.
RX   PubMed=34239127; DOI=10.1038/s41589-021-00823-5;
RA   Yu Y., Zheng Q., Erramilli S.K., Pan M., Park S., Xie Y., Li J., Fei J.,
RA   Kossiakoff A.A., Liu L., Zhao M.;
RT   "K29-linked ubiquitin signaling regulates proteotoxic stress response and
RT   cell cycle.";
RL   Nat. Chem. Biol. 17:896-905(2021).
RN   [21]
RP   FUNCTION, CATALYTIC ACTIVITY, AND PATHWAY.
RX   PubMed=33637724; DOI=10.1038/s41467-021-21715-1;
RA   Chen Y.H., Huang T.Y., Lin Y.T., Lin S.Y., Li W.H., Hsiao H.J., Yan R.L.,
RA   Tang H.W., Shen Z.Q., Chen G.C., Wu K.P., Tsai T.F., Chen R.H.;
RT   "VPS34 K29/K48 branched ubiquitination governed by UBE3C and TRABID
RT   regulates autophagy, proteostasis and liver metabolism.";
RL   Nat. Commun. 12:1322-1322(2021).
RN   [22] {ECO:0007744|PDB:6K2C}
RP   X-RAY CRYSTALLOGRAPHY (2.70 ANGSTROMS) OF 693-1083, FUNCTION, CATALYTIC
RP   ACTIVITY, AUTOUBIQUITINATION, UBIQUITINATION AT LYS-903, AND MUTAGENESIS OF
RP   758-ASN--LEU-762; GLN-961; LYS-1013 AND SER-1049.
RX   PubMed=32039437; DOI=10.1042/bcj20200027;
RA   Singh S., Sivaraman J.;
RT   "Crystal structure of HECT domain of UBE3C E3 ligase and its ubiquitination
RT   activity.";
RL   Biochem. J. 477:905-923(2020).
CC   -!- FUNCTION: E3 ubiquitin-protein ligase that specifically catalyzes 'Lys-
CC       29'- and 'Lys-48'-linked polyubiquitin chains (PubMed:11278995,
CC       PubMed:12692129, PubMed:16341092, PubMed:16601690, PubMed:24811749,
CC       PubMed:24158444, PubMed:25752573, PubMed:25752577, PubMed:34239127,
CC       PubMed:33637724, PubMed:32039437). Accepts ubiquitin from the E2
CC       ubiquitin-conjugating enzyme UBE2D1 in the form of a thioester and then
CC       directly transfers the ubiquitin to targeted substrates
CC       (PubMed:9575161, PubMed:32039437). Associates with the proteasome and
CC       promotes elongation of ubiquitin chains on substrates bound to the 26S
CC       proteasome (PubMed:24158444, PubMed:28396413, PubMed:31375563). Also
CC       catalyzes 'Lys-29'- and 'Lys-48'-linked ubiquitination of 26S
CC       proteasome subunit ADRM1/RPN13 in response to proteotoxic stress,
CC       impairing the ability of the proteasome to bind and degrade ubiquitin-
CC       conjugated proteins (PubMed:24811749, PubMed:31375563). Acts as a
CC       negative regulator of autophagy by mediating 'Lys-29'- and 'Lys-48'-
CC       linked ubiquitination of PIK3C3/VPS34, promoting its degradation
CC       (PubMed:33637724). Can assemble unanchored poly-ubiquitin chains in
CC       either 'Lys-29'- or 'Lys-48'-linked polyubiquitin chains; with some
CC       preference for 'Lys-48' linkages (PubMed:11278995, PubMed:16601690,
CC       PubMed:25752577). Acts as a negative regulator of type I interferon by
CC       mediating 'Lys-48'-linked ubiquitination of IRF3 and IRF7, leading to
CC       their degradation by the proteasome (PubMed:21167755). Catalyzes
CC       ubiquitination and degradation of CAND2 (PubMed:12692129).
CC       {ECO:0000269|PubMed:11278995, ECO:0000269|PubMed:12692129,
CC       ECO:0000269|PubMed:16341092, ECO:0000269|PubMed:16601690,
CC       ECO:0000269|PubMed:21167755, ECO:0000269|PubMed:24158444,
CC       ECO:0000269|PubMed:24811749, ECO:0000269|PubMed:25752573,
CC       ECO:0000269|PubMed:25752577, ECO:0000269|PubMed:28396413,
CC       ECO:0000269|PubMed:31375563, ECO:0000269|PubMed:32039437,
CC       ECO:0000269|PubMed:33637724, ECO:0000269|PubMed:34239127,
CC       ECO:0000269|PubMed:9575161}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=S-ubiquitinyl-[E2 ubiquitin-conjugating enzyme]-L-cysteine +
CC         [acceptor protein]-L-lysine = [E2 ubiquitin-conjugating enzyme]-L-
CC         cysteine + N(6)-ubiquitinyl-[acceptor protein]-L-lysine.;
CC         EC=2.3.2.26; Evidence={ECO:0000269|PubMed:11278995,
CC         ECO:0000269|PubMed:24158444, ECO:0000269|PubMed:24811749,
CC         ECO:0000269|PubMed:25752573, ECO:0000269|PubMed:25752577,
CC         ECO:0000269|PubMed:32039437, ECO:0000269|PubMed:33637724,
CC         ECO:0000269|PubMed:34239127};
CC   -!- PATHWAY: Protein modification; protein ubiquitination.
CC       {ECO:0000269|PubMed:11278995, ECO:0000269|PubMed:12692129,
CC       ECO:0000269|PubMed:16601690, ECO:0000269|PubMed:21167755,
CC       ECO:0000269|PubMed:24158444, ECO:0000269|PubMed:24811749,
CC       ECO:0000269|PubMed:25752573, ECO:0000269|PubMed:25752577,
CC       ECO:0000269|PubMed:33637724, ECO:0000269|PubMed:34239127}.
CC   -!- SUBUNIT: Interacts with 26S proteasomes (PubMed:12692129,
CC       PubMed:24158444). Interacts (via the HECT domain) with UBE2D1 and, less
CC       efficiently, with UBE2L3 (PubMed:11278995, PubMed:9575161).
CC       {ECO:0000269|PubMed:11278995, ECO:0000269|PubMed:12692129,
CC       ECO:0000269|PubMed:24158444, ECO:0000269|PubMed:9575161}.
CC   -!- INTERACTION:
CC       Q15386; Q08379: GOLGA2; NbExp=3; IntAct=EBI-1058871, EBI-618309;
CC       Q15386-3; P23560-2: BDNF; NbExp=3; IntAct=EBI-25833079, EBI-12275524;
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=3;
CC       Name=1;
CC         IsoId=Q15386-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q15386-2; Sequence=VSP_013956, VSP_013957;
CC       Name=3;
CC         IsoId=Q15386-3; Sequence=VSP_013953, VSP_013954, VSP_013955;
CC   -!- TISSUE SPECIFICITY: Highly expressed in skeletal muscle. Detected at
CC       much lower levels in kidney and pancreas. {ECO:0000269|PubMed:11278995,
CC       ECO:0000269|PubMed:12692129, ECO:0000269|PubMed:9575161}.
CC   -!- PTM: Autoubiquitinated; promoting its own degradation.
CC       {ECO:0000269|PubMed:11278995, ECO:0000269|PubMed:25752573,
CC       ECO:0000269|PubMed:32039437}.
CC   -!- SIMILARITY: Belongs to the UBE3C family. {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=BAA02799.2; Type=Erroneous initiation; Note=Extended N-terminus.; Evidence={ECO:0000305};
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; D13635; BAA02799.2; ALT_INIT; mRNA.
DR   EMBL; AC004898; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC004975; AAD51453.1; -; Genomic_DNA.
DR   EMBL; CH236954; EAL23922.1; -; Genomic_DNA.
DR   EMBL; CH471149; EAX04568.1; -; Genomic_DNA.
DR   EMBL; BC014029; AAH14029.1; -; mRNA.
DR   EMBL; BC026241; AAH26241.1; -; mRNA.
DR   CCDS; CCDS34789.1; -. [Q15386-1]
DR   PIR; A38919; A38919.
DR   RefSeq; NP_055486.2; NM_014671.2. [Q15386-1]
DR   PDB; 6K2C; X-ray; 2.70 A; A=693-1083.
DR   PDBsum; 6K2C; -.
DR   AlphaFoldDB; Q15386; -.
DR   SMR; Q15386; -.
DR   BioGRID; 115043; 228.
DR   IntAct; Q15386; 29.
DR   MINT; Q15386; -.
DR   STRING; 9606.ENSP00000309198; -.
DR   GlyGen; Q15386; 1 site, 1 O-linked glycan (1 site).
DR   iPTMnet; Q15386; -.
DR   PhosphoSitePlus; Q15386; -.
DR   SwissPalm; Q15386; -.
DR   BioMuta; UBE3C; -.
DR   DMDM; 67462009; -.
DR   EPD; Q15386; -.
DR   jPOST; Q15386; -.
DR   MassIVE; Q15386; -.
DR   MaxQB; Q15386; -.
DR   PaxDb; Q15386; -.
DR   PeptideAtlas; Q15386; -.
DR   ProteomicsDB; 60555; -. [Q15386-1]
DR   ProteomicsDB; 60556; -. [Q15386-2]
DR   ProteomicsDB; 60557; -. [Q15386-3]
DR   Antibodypedia; 33178; 173 antibodies from 26 providers.
DR   DNASU; 9690; -.
DR   Ensembl; ENST00000348165.10; ENSP00000309198.8; ENSG00000009335.18. [Q15386-1]
DR   Ensembl; ENST00000389103.4; ENSP00000373755.4; ENSG00000009335.18. [Q15386-3]
DR   Ensembl; ENST00000611269.4; ENSP00000481584.1; ENSG00000009335.18. [Q15386-3]
DR   GeneID; 9690; -.
DR   KEGG; hsa:9690; -.
DR   MANE-Select; ENST00000348165.10; ENSP00000309198.8; NM_014671.3; NP_055486.2.
DR   UCSC; uc003wnf.3; human. [Q15386-1]
DR   AGR; HGNC:16803; -.
DR   CTD; 9690; -.
DR   DisGeNET; 9690; -.
DR   GeneCards; UBE3C; -.
DR   HGNC; HGNC:16803; UBE3C.
DR   HPA; ENSG00000009335; Low tissue specificity.
DR   MIM; 614454; gene.
DR   neXtProt; NX_Q15386; -.
DR   OpenTargets; ENSG00000009335; -.
DR   PharmGKB; PA134905339; -.
DR   VEuPathDB; HostDB:ENSG00000009335; -.
DR   eggNOG; KOG0942; Eukaryota.
DR   GeneTree; ENSGT00940000156321; -.
DR   HOGENOM; CLU_002173_2_1_1; -.
DR   InParanoid; Q15386; -.
DR   OMA; MRVQGHL; -.
DR   OrthoDB; 1386at2759; -.
DR   PhylomeDB; Q15386; -.
DR   TreeFam; TF106144; -.
DR   BRENDA; 2.3.2.26; 2681.
DR   PathwayCommons; Q15386; -.
DR   Reactome; R-HSA-983168; Antigen processing: Ubiquitination & Proteasome degradation.
DR   SignaLink; Q15386; -.
DR   SIGNOR; Q15386; -.
DR   UniPathway; UPA00143; -.
DR   BioGRID-ORCS; 9690; 26 hits in 1209 CRISPR screens.
DR   ChiTaRS; UBE3C; human.
DR   GeneWiki; UBE3C; -.
DR   GenomeRNAi; 9690; -.
DR   Pharos; Q15386; Tbio.
DR   PRO; PR:Q15386; -.
DR   Proteomes; UP000005640; Chromosome 7.
DR   RNAct; Q15386; protein.
DR   Bgee; ENSG00000009335; Expressed in sural nerve and 206 other tissues.
DR   ExpressionAtlas; Q15386; baseline and differential.
DR   Genevisible; Q15386; HS.
DR   GO; GO:0000502; C:proteasome complex; IEA:UniProtKB-KW.
DR   GO; GO:0019210; F:kinase inhibitor activity; IDA:UniProt.
DR   GO; GO:0061630; F:ubiquitin protein ligase activity; IDA:UniProtKB.
DR   GO; GO:0035519; P:protein K29-linked ubiquitination; IDA:UniProtKB.
DR   GO; GO:0070936; P:protein K48-linked ubiquitination; IDA:UniProtKB.
DR   GO; GO:0000209; P:protein polyubiquitination; IDA:UniProtKB.
DR   GO; GO:0006511; P:ubiquitin-dependent protein catabolic process; IDA:UniProt.
DR   CDD; cd00078; HECTc; 1.
DR   Gene3D; 3.30.2160.10; Hect, E3 ligase catalytic domain; 1.
DR   Gene3D; 3.30.2410.10; Hect, E3 ligase catalytic domain; 1.
DR   Gene3D; 3.90.1750.10; Hect, E3 ligase catalytic domains; 1.
DR   InterPro; IPR044611; E3A/B/C-like.
DR   InterPro; IPR000569; HECT_dom.
DR   InterPro; IPR035983; Hect_E3_ubiquitin_ligase.
DR   InterPro; IPR000048; IQ_motif_EF-hand-BS.
DR   PANTHER; PTHR45700; UBIQUITIN-PROTEIN LIGASE E3C; 1.
DR   PANTHER; PTHR45700:SF2; UBIQUITIN-PROTEIN LIGASE E3C; 1.
DR   Pfam; PF00632; HECT; 1.
DR   SMART; SM00119; HECTc; 1.
DR   SMART; SM00015; IQ; 1.
DR   SUPFAM; SSF56204; Hect, E3 ligase catalytic domain; 1.
DR   PROSITE; PS50237; HECT; 1.
DR   PROSITE; PS50096; IQ; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Direct protein sequencing;
KW   Isopeptide bond; Proteasome; Reference proteome; Transferase;
KW   Ubl conjugation; Ubl conjugation pathway.
FT   CHAIN           1..1083
FT                   /note="Ubiquitin-protein ligase E3C"
FT                   /id="PRO_0000194982"
FT   DOMAIN          45..74
FT                   /note="IQ"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00116"
FT   DOMAIN          744..1083
FT                   /note="HECT"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00104"
FT   REGION          1..60
FT                   /note="Cis-determinant of acceptor ubiquitin-binding"
FT                   /evidence="ECO:0000269|PubMed:16341092"
FT   REGION          1..40
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          355..385
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        16..40
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   ACT_SITE        1051
FT                   /note="Glycyl thioester intermediate"
FT                   /evidence="ECO:0000305|PubMed:12692129,
FT                   ECO:0000305|PubMed:21167755, ECO:0000305|PubMed:24158444,
FT                   ECO:0000305|PubMed:24811749, ECO:0000305|PubMed:25752573"
FT   CROSSLNK        903
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in ubiquitin); by autocatalysis"
FT                   /evidence="ECO:0000269|PubMed:32039437"
FT   VAR_SEQ         23..65
FT                   /note="Missing (in isoform 3)"
FT                   /evidence="ECO:0000303|PubMed:15489334"
FT                   /id="VSP_013953"
FT   VAR_SEQ         445..447
FT                   /note="LLY -> VYK (in isoform 3)"
FT                   /evidence="ECO:0000303|PubMed:15489334"
FT                   /id="VSP_013954"
FT   VAR_SEQ         448..1083
FT                   /note="Missing (in isoform 3)"
FT                   /evidence="ECO:0000303|PubMed:15489334"
FT                   /id="VSP_013955"
FT   VAR_SEQ         640..649
FT                   /note="TQLYVPASRH -> LLKDLFNIYH (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:15489334"
FT                   /id="VSP_013956"
FT   VAR_SEQ         650..1083
FT                   /note="Missing (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:15489334"
FT                   /id="VSP_013957"
FT   MUTAGEN         758..762
FT                   /note="NAHGL->AAAAA: Abolished E3 ubiquitin-protein ligase
FT                   activity."
FT                   /evidence="ECO:0000269|PubMed:32039437"
FT   MUTAGEN         961
FT                   /note="Q->A,E: Reduced E3 ubiquitin-protein ligase
FT                   activity."
FT                   /evidence="ECO:0000269|PubMed:32039437"
FT   MUTAGEN         1013
FT                   /note="K->Q: Increased E3 ubiquitin-protein ligase
FT                   activity."
FT                   /evidence="ECO:0000269|PubMed:32039437"
FT   MUTAGEN         1049
FT                   /note="S->H: Reduced E3 ubiquitin-protein ligase activity."
FT                   /evidence="ECO:0000269|PubMed:32039437"
FT   MUTAGEN         1051
FT                   /note="C->A: Abolishes E3 ubiquitin-protein ligase
FT                   activity. No stimulation of in vitro CAND2 ubiquitination."
FT                   /evidence="ECO:0000269|PubMed:12692129,
FT                   ECO:0000269|PubMed:21167755, ECO:0000269|PubMed:24158444,
FT                   ECO:0000269|PubMed:24811749, ECO:0000269|PubMed:25752573"
FT   CONFLICT        822
FT                   /note="G -> A (in Ref. 1; BAA02799)"
FT                   /evidence="ECO:0000305"
FT   HELIX           695..712
FT                   /evidence="ECO:0007829|PDB:6K2C"
FT   STRAND          723..727
FT                   /evidence="ECO:0007829|PDB:6K2C"
FT   HELIX           729..731
FT                   /evidence="ECO:0007829|PDB:6K2C"
FT   HELIX           732..739
FT                   /evidence="ECO:0007829|PDB:6K2C"
FT   TURN            742..744
FT                   /evidence="ECO:0007829|PDB:6K2C"
FT   STRAND          752..756
FT                   /evidence="ECO:0007829|PDB:6K2C"
FT   HELIX           770..784
FT                   /evidence="ECO:0007829|PDB:6K2C"
FT   HELIX           787..789
FT                   /evidence="ECO:0007829|PDB:6K2C"
FT   STRAND          790..794
FT                   /evidence="ECO:0007829|PDB:6K2C"
FT   STRAND          796..798
FT                   /evidence="ECO:0007829|PDB:6K2C"
FT   STRAND          800..802
FT                   /evidence="ECO:0007829|PDB:6K2C"
FT   HELIX           806..810
FT                   /evidence="ECO:0007829|PDB:6K2C"
FT   HELIX           814..830
FT                   /evidence="ECO:0007829|PDB:6K2C"
FT   HELIX           841..848
FT                   /evidence="ECO:0007829|PDB:6K2C"
FT   TURN            929..932
FT                   /evidence="ECO:0007829|PDB:6K2C"
FT   HELIX           933..944
FT                   /evidence="ECO:0007829|PDB:6K2C"
FT   HELIX           949..952
FT                   /evidence="ECO:0007829|PDB:6K2C"
FT   HELIX           957..965
FT                   /evidence="ECO:0007829|PDB:6K2C"
FT   HELIX           973..978
FT                   /evidence="ECO:0007829|PDB:6K2C"
FT   STRAND          981..983
FT                   /evidence="ECO:0007829|PDB:6K2C"
FT   HELIX           991..1001
FT                   /evidence="ECO:0007829|PDB:6K2C"
FT   HELIX           1005..1016
FT                   /evidence="ECO:0007829|PDB:6K2C"
FT   HELIX           1026..1028
FT                   /evidence="ECO:0007829|PDB:6K2C"
FT   STRAND          1034..1037
FT                   /evidence="ECO:0007829|PDB:6K2C"
FT   STRAND          1047..1049
FT                   /evidence="ECO:0007829|PDB:6K2C"
FT   HELIX           1050..1052
FT                   /evidence="ECO:0007829|PDB:6K2C"
FT   STRAND          1054..1057
FT                   /evidence="ECO:0007829|PDB:6K2C"
FT   HELIX           1063..1077
FT                   /evidence="ECO:0007829|PDB:6K2C"
SQ   SEQUENCE   1083 AA;  123923 MW;  BD437ABA457A0DDA CRC64;
     MFSFEGDFKT RPKVSLGGAS RKEEKASLLH RTQEERRKRE EERRRLKNAI IIQSFIRGYR
     DRKQQYSIQR SAFDRCATLS QSGGAFPIAN GPNLTLLVRQ LLFFYKQNED SKRLIWLYQN
     LIKHSSLFVK QLDGSERLTC LFQIKRLMSL CCRLLQNCND DSLNVALPMR MLEVFSSENT
     YLPVLQDASY VVSVIEQILH YMIHNGYYRS LYLLINSKLP SSIEYSDLSR VPIAKILLEN
     VLKPLHFTYN SCPEGARQQV FTAFTEEFLA APFTDQIFHF IIPALADAQT VFPYEPFLNA
     LLLIESRCSR KSGGAPWLFY FVLTVGENYL GALSEEGLLV YLRVLQTFLS QLPVSPASAS
     CHDSASDSEE ESEEADKPSS PEDGRLSVSY ITEECLKKLD TKQQTNTLLN LVWRDSASEE
     VFTTMASVCH TLMVQHRMMV PKVRLLYSLA FNARFLRHLW FLISSMSTRM ITGSMVPLLQ
     VISRGSPMSF EDSSRIIPLF YLFSSLFSHS LISIHDNEFF GDPIEVVGQR QSSMMPFTLE
     ELIMLSRCLR DACLGIIKLA YPETKPEVRE EYITAFQSIG VTTSSEMQQC IQMEQKRWIQ
     LFKVITNLVK MLKSRDTRRN FCPPNHWLSE QEDIKADKVT QLYVPASRHV WRFRRMGRIG
     PLQSTLDVGL ESPPLSVSEE RQLAVLTELP FVVPFEERVK IFQRLIYADK QEVQGDGPFL
     DGINVTIRRN YIYEDAYDKL SPENEPDLKK RIRVHLLNAH GLDEAGIDGG GIFREFLNEL
     LKSGFNPNQG FFKTTNEGLL YPNPAAQMLV GDSFARHYYF LGRMLGKALY ENMLVELPFA
     GFFLSKLLGT SADVDIHHLA SLDPEVYKNL LFLKSYEDDV EELGLNFTVV NNDLGEAQVV
     ELKFGGKDIP VTSANRIAYI HLVADYRLNR QIRQHCLAFR QGLANVVSLE WLRMFDQQEI
     QVLISGAQVP ISLEDLKSFT NYSGGYSADH PVIKVFWRVV EGFTDEEKRK LLKFVTSCSR
     PPLLGFKELY PAFCIHNGGS DLERLPTAST CMNLLKLPEF YDETLLRSKL LYAIECAAGF
     ELS
//
